Skip to Content
MilliporeSigma
All Photos(3)

Key Documents

17-656

Sigma-Aldrich

ChIPAb+ Sox-2, clone 6F1.2 - ChIP Validated Antibody and Primer Set

clone 6F1.2, from mouse

Synonym(s):

Transcription factor SOX-2, SOX2

Sign Into View Organizational & Contract Pricing

Select a Size

25 ASSAYS
$580.00

$580.00


Estimated to ship onApril 21, 2025


Request a Bulk Order

Select a Size

Change View
25 ASSAYS
$580.00

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.52

$580.00


Estimated to ship onApril 21, 2025


Request a Bulk Order

biological source

mouse

Quality Level

clone

6F1.2, monoclonal

species reactivity

human, mouse

manufacturer/tradename

ChIPAb+
Upstate®

technique(s)

ChIP: suitable
dot blot: suitable
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG2bκ

NCBI accession no.

UniProt accession no.

shipped in

dry ice

Related Categories

General description

All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction.
The ChIPAb+ Sox-2, clone 6F1.2 antibody/primer set includes the Sox-2, clone 6F1.2 antibody, a negative control antibody (purified mouse IgG), and qPCR primers which amplify a 95 bp region within the promoter of the human nanog gene. The Sox-2, clone 6F1.2 antibody and negative control antibodies are supplied in a scalable "per ChIP" reaction size and can be used to functionally validate the precipitation of Sox-2-associated chromatin.

Sox-2 plays a key role in embryonic stem cell development, and has been shown to help stem cells maintain pluripotent potential. It has also been shown to be associated with uncommitted dividing stem cell and precursor cells of the developing CNS.

Specificity

Not tested in other species.
Recognizes Sox-2, MW: ~34 kDa.

Immunogen

Recombinant GST Fusion protein.

Application

Please refer to the EZ-Magna G ChIP (Cat. No. 17-409) or EZ-ChIP (Cat. No. 17-371) protocol for experimental details.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology

Transcription Factors
This ChIPAb+ Sox-2, clone 6F1.2 -ChIP Validated Antibody & Primer Set conveniently includes the antibody & the specific control PCR primers.

Packaging

25 assays per set. Recommended use: ~4 μg antibody per chromatin immunoprecipitation (dependent upon biological context).

Components

Anti-Sox-2, clone 6F1.2 (mouse monoclonal IgG), Part No. CS204373.
One vial containing 100 μg of protein A purified antibody in 140 μL of 0.02 M phosphate buffer pH 7.6 with 0.25 M NaCl containing 0.1% sodium azide, and 30% glycerol. Store at -20°C.

Normal Mouse IgG, Part No. CS200621.
One vial containing 125 μg of purified mouse IgG in 125 μL storage buffer containing 0.1% sodium azide. Store at -20°C.

ChIP Primers, nanog promoter,
Part No. CS204374. One vial containing 75 μL of 5 μM of each primer specific for the promoter region of human nanog.
Store at -20°C.
FOR: GTT CTG TTG CTC GGT TTT CT
REV: TCC CGT CTA CCA GTC TCA CC

Quality

Chromatin Immunoprecipitation:
Sonicated chromatin prepared from Ntera 2 cells (3 X 106 cell equivalents per IP) were subjected to chromatin immunoprecipitation using 4 µg of either a normal mouse IgG, or Anti-Sox-2, clone 6F1.2 antibody and the Magna ChIP® G Kit (Cat. No. 17-611). Successful immunoprecipitation of Sox-2-associated DNA fragments was verified by qPCR using ChIP Primers, nanog promoter (Figure 1).
Please refer to the EZ-Magna ChIP G (Cat. No. 17-409) or EZ-ChIP (Cat. No. 17-371) protocol for experimental details.

Target description

~34 kDa

Physical form

Format: Purified

Storage and Stability

Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Analysis Note

Control
Includes negative control mouse IgG antibody and primers specific for human nanog promoter region.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

MAGNA CHIP is a registered trademark of Merck KGaA, Darmstadt, Germany
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class

10 - Combustible liquids


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jasmin M Siegle et al.
Nature communications, 5, 4511-4511 (2014-08-01)
Although the principles that balance stem cell self-renewal and differentiation in normal tissue homeostasis are beginning to emerge, it is still unclear whether cancer cells with tumour initiating potential are similarly governed, or whether they have acquired distinct mechanisms to
Ellen Voigt et al.
Molecular cancer research : MCR, 19(12), 2015-2025 (2021-10-02)
Although many cancer prognoses have improved in the past 50 years due to advancements in treatments, there has been little improvement in therapies for small-cell lung cancer (SCLC). One promising avenue to improve treatment for SCLC is to understand its

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service